Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(22 sites)
United States
MD Anderson, Houston, Texas Armenia
Erebuni Medical Center, Yerevan Hematology Center After Prof. R. Yeolyan (Adult Blood Disorders), Yerevan Hematology Center After Prof. R. Yeolyan (Clinic of Adults Oncology), Yerevan National Center of Oncology Named After V.A. Fanarjyan, Yerevan Bulgaria
Complex Oncology Center - Plovdiv - Base II, Plovdiv Poland
Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p., Wroclaw Romania
Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu, Bucharest Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca Slovakia
Summit Clinical Research s.r.o, Bratislava Spain
START Barcelona - Hospital HM Nou Delfos, Barcelona Hospital Universitari Dexeus - Grupo Quirónsalud, Barcelona START Rioja - Hospital de San Pedro, La Rioja Hospital Universitari Arnau de Vilanova, Lleida START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid Hospital Universitario La Paz, Madrid START Madrid - CIOCC - HM Sanchinarro, Madrid Hospital Universitario 12 de Octubre, Madrid Hospital Clínico Universitario Virgen de la Arrixaca (Hematology Dept), Murcia Hospital Clínico Universitario Virgen de la Arrixaca (Solid Tumor Dept), Murcia Hospital Universitari i Politècnic La Fe, Valencia